Team5 - 2024

02/09/2024

Original Articles

1 - Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis. Gavoille A, Rollot F, Casey R, Kerbrat A, Le Page E, Bigaut K, Mathey G, Michel L, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Manchon E, Lapergue B, Wiertlewski S, De Sèze J, Vukusic S, Laplaud DA; OFSEP Investigators. **2024** *JAMA Neurol.* PMID 38949816

2 - Blood MMP-9 measured at 2 years after lung transplantation as a prognostic biomarker of chronic lung allograft dysfunction Tissot A, Durand E, Goronflot T, Coiffard B, Renaud-Picard B, Roux A, Demant X, Mornex JF, Falque L, Salpin M, Le Pavec J, Villeneuve T, Boussaud V, Knoop C, Magnan A, Lair D, Berthelot L, Danger R, Brouard S; COLT consortium. **2024** *Respir Res.* PMID 38336710

3 - COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022. Jeantin L, Januel E, Labauge P, Maillart E, de Seze J, Zéphir H, Pelletier J, Kerschen P, Biotti D, Heinzlef O, Guilloton L, Bensa C, Théaudin M, Vukusic S, Casez O, Maurousset A, Laplaud D, Berger E, Lebrun-Frenay C, Bourre B, Branger P, Stankoff B, Clavelou P, Thouvenot E, Manchon E, Moreau T, Sellal F, Zedet M, Papeix C, Louapre C. **2024** *Mult Scler.* PMID 38247113

4 - Design, cohort profile and comparison of the KTD-Innov study: a prospective multidimensional biomarker validation study in kidney allograft rejection Goutaudier V, Sablik M, Racapé M, Rousseau O, Audry B, Kamar N, Raynaud M, Aubert O, Charreau B, Papuchon E, Danger R, Letertre L, Couzi L, Morelon E, Le Quintrec M, Taupin JL, Vicaut E, Legendre C, Le Mai H, Potluri V, Nguyen TV, Azoury ME, Pinheiro A, Nouadje G, Sonigo P, Anglicheau D, Tieken I, Vogelaar S, Jacquelinet C, Reese P, Gourraud PA, Brouard S, Lefaucheur C, Loupy A; KTD-Innov Consortium. **2024** *Eur J Epidemiol.* PMID 38625480

5 - Disentangling Multiple Sclerosis heterogeneity in the French territory among genetic and environmental factors via Bayesian heritability analysis. Nova A, Bourguiba-Hachemi S, Vince N, Gourraud PA, Bernardinelli L, Fazia T. **2024** *Mult Scler Relat Disord.* PMID 38880029

6 - Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults: The MOGADOR2 Study. Deschamps R, Guillaume J, Ciron J, Audoin B, Ruet A, Maillart E, Pique J, Benyahya L, Laplaud DA, Michel L, Collongues N, Cohen M, Ayrignac X, Thouvenot E, Zephir H, Bourre B, Froment Tilikete C, Moreau T, Cantagrel P, Kerschen P, Cabasson S, Maubeuge N, Hankiewicz K, Nifle C, Berger E, Megherbi H, Magy L, Klapczynski F, Sarov Riviere M, Giannesini C, Hamelin L, Giroux M, Branger P, Maurousset A, Mathey G, Moulin M, Mélé N, Papeix C, Marignier R; as the NOMADMUS study group. **2024** *Neurology.* PMID 38991174

7 - High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS. Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Collongues N, Kerbrat A; OFSEP Investigators. **2024** *JAMA Neurol.* PMID 38526462

8 - Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis. Benallegue N, Rollot F, Wiertlewski S, Casey R, Debouverie M, Kerbrat A, De Seze J, Ciron J, Ruet A, Labauge P, Maillart E, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Heinzlef O, Pelletier J, Thouvenot E, Al Khedr A, Bourre B, Casez O, Cabre P, Wahab A, Magy L, Vukusic S, Laplaud DA; OFSEP (Observatoire Français de la Sclérose en Plaques) Investigators. **2024** *JAMA Neurol.* PMID 38345791

9 - Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study Boussamet L, Montassier E, Mathé C, Garcia A, Morille J, Shah S, Dugast E, Wiertlewski S, Gourdel M, Bang C, Stürner KH, Masson D, Nicot AB, Vince N, Laplaud DA, Feinstein DL, Berthelot L. **2024** *Sci Rep.* PMID 38565581

10 - Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort Study. Blant JC, De Rossi NN, Gold R, Maurousset A, Kraemer M, Romero-Pinel L, Misu T, Ouallet JC, Pallix Guyot M, Gerevini S, Bakirtzis C, Piñar Morales R, Vlad B, Karypidis P, Moisset X, Derfuss TJ, Jelcic I, Martin-Blondel G, Ayzenberg I, McGraw C, Laplaud DA, Du Pasquier RA, Bernard-Valnet R; for CORPUS and Italian study groups. **2024** *Neurol Neuroimmunol Neuroinflamm.* PMID 38991170

11 - Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study. Marignier R, Laplaud D, Zéphir H, Papeix C, Leray E, Amri E, Piotaix M, de Sèze J. **2024** *Front Neurol.* PMID 38318238

12 - Sepsis-trained macrophages promote antitumoral tissue-resident T cells. Broquet A, Gourain V, Goronflot T, Le Mabecque V, Sinha D, Ashayeripanah M, Jacqueline C, Martin P, Davieau M, Boutin L, Poulain C, Martin FP, Fourgeux C, Petrier M, Cannevet M, Leclercq T, Guillonneau M, Chaumette T, Laurent T, Harly C, Scotet E, Legentil L, Ferrières V, Corgnac S, Mami-Chouaib F, Mosnier JF, Mauduit N, McWilliam HEG, Villadangos JA, Gourraud PA, Asehnoune K, Poschmann J, Roquilly A. **2024** *Nat Immunol.* PMID 38684922

13 - Predictive Models of Long-Term Outcome in Patients with Moderate to Severe Traumatic Brain Injury are Biased Toward Mortality Prediction. Martin FP, Goronflot T, Moyer JD, Huet O, Asehnoune K, Cinotti R, Gourraud PA, Roquilly A. **2024** *Neurocrit Care.* PMID 39138720

14 - Flexibility of a large blindly synthetized avatar database for occupational research: Example from the CONSTANCES cohort for stroke and knee pain. Fadel M, Petot J, Gourraud PA, Descatha A. **2024** *PloS One.* PMID 39083487

Review, Editorial, Comments

1 - Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations. Deschamps R, Papeix C, Ayrignac X, Bourre B, Ciron J, Cohen M, Collongues N, Deiva K, Durand Dubief F, Laplaud DA, Maillart E, Michel L, Pique J, Ruet A, Thouvenot E, Zéphir H, Marignier R, Audoin B. **2024** *Rev Neurol.* PMID 38969609

2 - Clinical applications of deep learning in neuroinflammatory diseases: A scoping review. Demuth S, Paris J, Faddeenkov I, De Sèze J, Gourraud PA. **2024** *Rev Neurol.* PMID 38772806

3 - Scoping review of clinical decision support systems for multiple sclerosis management: Leveraging information technology and massive health data Demuth S, Ed-Driouch C, Dumas C, Laplaud D, Edan G, Vince N, De Sèze J, Gourraud PA. **2024** *Eur J Neurol.* PMID 38860844